Dr. Mik Rinne on the First Promising CDK2 Inhibitor in Combination to Treat HR+/HER2- Breast Cancer

Blueprint Medicines recently new data regarding its CDK2 inhibitor, BLU-222, in patients with HR+/HER2-Breast Cancer. The data, which marks the first promising clinical results for a CDK2 inhibitor in combination with an approved CDK4/6 inhibitor, were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Mik Rinne, VP of Clinical Development at Blueprint , spoke to DocWire News about the exciting findings of this trial and its implications in the fight against breast cancer.